In brief: Rockeby, GTG, PharmAust, Mimotopes, Solbec

Rockeby Biomed (ASX:RBY) has lodged a prospectus to raise AUD$1.78 million through a non-renounceable one-for-one share rights issue. The issue price for each share is $0.01 and the company expects the capital to see it through to the end of financial year 2006.

Tom Howitt, currently chief financial officer at Genetic Technologies (ASX:GTG, OTC:GNTLY), will also take on the role as company secretary, replacing Ian Dennis.

John Thompson is PharmAust's (ASX:PAA) new non-executive chairman, replacing Paul D'Sylva who is now the managing director of PharmAust subsidiary Mimotopes. Non-executive directors Stuart Gunzburg, Thomas Picton-Warlow and Kee Kirk Chin have also resigned from the board of PharmAust which now comprises John Thompson and executive directors Paul D'Sylva, Bryant McLarty and Wayne Best.

Solbec Pharmaceuticals (ASX:SBP) has appointed Agenix's commercial counsel David Sparling as its business development manager, replacing Greg Barrington, who is pursuing other interests, according to the company.